These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 17520666)

  • 1. Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models.
    Qian DZ; Wei YF; Wang X; Kato Y; Cheng L; Pili R
    Prostate; 2007 Aug; 67(11):1182-93. PubMed ID: 17520666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo imaging of retinoic acid receptor beta2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells.
    Qian DZ; Ren M; Wei Y; Wang X; van de Geijn F; Rasmussen C; Nakanishi O; Sacchi N; Pili R
    Prostate; 2005 Jun; 64(1):20-8. PubMed ID: 15651062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
    Butler LM; Agus DB; Scher HI; Higgins B; Rose A; Cordon-Cardo C; Thaler HT; Rifkind RA; Marks PA; Richon VM
    Cancer Res; 2000 Sep; 60(18):5165-70. PubMed ID: 11016644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation.
    Camphausen K; Scott T; Sproull M; Tofilon PJ
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6066-71. PubMed ID: 15447991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
    Shabbeer S; Kortenhorst MS; Kachhap S; Galloway N; Rodriguez R; Carducci MA
    Prostate; 2007 Jul; 67(10):1099-110. PubMed ID: 17477369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors.
    Jaboin J; Wild J; Hamidi H; Khanna C; Kim CJ; Robey R; Bates SE; Thiele CJ
    Cancer Res; 2002 Nov; 62(21):6108-15. PubMed ID: 12414635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma.
    Dalgard CL; Van Quill KR; O'Brien JM
    Clin Cancer Res; 2008 May; 14(10):3113-23. PubMed ID: 18483379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells.
    Frønsdal K; Saatcioglu F
    Prostate; 2005 Feb; 62(3):299-306. PubMed ID: 15389787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model.
    Sargeant AM; Rengel RC; Kulp SK; Klein RD; Clinton SK; Wang YC; Chen CS
    Cancer Res; 2008 May; 68(10):3999-4009. PubMed ID: 18483287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation.
    Park JH; Jung Y; Kim TY; Kim SG; Jong HS; Lee JW; Kim DK; Lee JS; Kim NK; Kim TY; Bang YJ
    Clin Cancer Res; 2004 Aug; 10(15):5271-81. PubMed ID: 15297431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma.
    Lai JP; Yu C; Moser CD; Aderca I; Han T; Garvey TD; Murphy LM; Garrity-Park MM; Shridhar V; Adjei AA; Roberts LR
    Gastroenterology; 2006 Jun; 130(7):2130-44. PubMed ID: 16762634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors.
    Fournel M; Trachy-Bourget MC; Yan PT; Kalita A; Bonfils C; Beaulieu C; Frechette S; Leit S; Abou-Khalil E; Woo SH; Delorme D; MacLeod AR; Besterman JM; Li Z
    Cancer Res; 2002 Aug; 62(15):4325-30. PubMed ID: 12154036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
    Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
    Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Piperazine-designed alpha 1A/alpha 1D-adrenoceptor blocker KMUP-1 and doxazosin provide down-regulation of androgen receptor and PSA in prostatic LNCaP cells growth and specifically in xenografts.
    Liu CM; Lo YC; Tai MH; Wu BN; Wu WJ; Chou YH; Chai CY; Huang CH; Chen IJ
    Prostate; 2009 May; 69(6):610-23. PubMed ID: 19143029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent in vivo anti-breast cancer activity of IN-2001, a novel inhibitor of histone deacetylase, in MMTV/c-Neu mice.
    Joung KE; Min KN; An JY; Kim DK; Kong G; Sheen YY
    Cancer Res; 2006 May; 66(10):5394-402. PubMed ID: 16707467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
    Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor.
    Kim DH; Lee J; Kim KN; Kim HJ; Jeung HC; Chung HC; Kwon HJ
    Biochem Biophys Res Commun; 2007 Apr; 356(1):233-8. PubMed ID: 17353008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-Chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU) inhibits prostate carcinoma cell growth via p53-dependent and p53-independent pathways.
    Huynh H; Nguyen TH; Panasci L; Do P
    Cancer; 2004 Dec; 101(12):2881-91. PubMed ID: 15529313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells.
    Lee BI; Park SH; Kim JW; Sausville EA; Kim HT; Nakanishi O; Trepel JB; Kim SJ
    Cancer Res; 2001 Feb; 61(3):931-4. PubMed ID: 11221885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The therapeutic and preventive effect of RRR-alpha-vitamin E succinate on prostate cancer via induction of insulin-like growth factor binding protein-3.
    Yin Y; Ni J; Chen M; DiMaggio MA; Guo Y; Yeh S
    Clin Cancer Res; 2007 Apr; 13(7):2271-80. PubMed ID: 17404112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.